Effect of Toxoplasma gondii on colon cancer growth in mouse model

Despite all advances in cancer treatment methods, failure of treatment is a major concern. This failure can be caused by tumor environment made by tumor cells and prevents immune system to reach neoplastic cells. So, cancer immunotherapy and target therapy are in the focus of scientists. Due to the inverse relationship shown between parasites and cancer, parasites are a candidate for use in cancer immunotherapy. Toxoplasma gondii is an intracellular parasite invades many cells of vertebrae spices but make symptoms only in fetus and immuno-deficient person. Studies have shown T. gondii can stimulate immune system against neoplastic cells and break fort of tumor environment. In this experimental work, Colon cancer bearing mice randomly divided into three groups. Groups 1 and 2 were injected with either lysate or irradiated tachyzoite of T. gondii respectively. The third group were left intact as control group. Our resulted data showed that in irradiated tachyzoite or lysate treated groups there was a significant reduction in tumor growth in comparison with control group. However, the difference in survival time was not statistically significant. In conclusion, treatment with T. gondii antigens resulted in suppression of tumor growth.

Download Full-text

Effect of Toxoplasma gondii on colon cancer growth in mouse model

American Journal of BioMedicine ◽

10.18081/2333-5106/021-2/156-163 ◽

2021 ◽

Vol 9 (4) ◽

pp. 168-176

Keyword(s):

Colon Cancer ◽

Immune System ◽

Toxoplasma Gondii ◽

Mouse Model ◽

Tumor Growth ◽

Cancer Immunotherapy ◽

Target Therapy ◽

Control Group ◽

Neoplastic Cells ◽

Tumor Environment

Download Full-text

Emerging nanomedicines for effective breast cancer immunotherapy

Journal of Nanobiotechnology ◽

10.1186/s12951-020-00741-z ◽

2020 ◽

Vol 18 (1) ◽

Author(s):

Amirhossein Bahreyni ◽

Yasir Mohamud ◽

Honglin Luo

Keyword(s):

Breast Cancer ◽

Immune System ◽

Cancer Immunotherapy ◽

Immune Cells ◽

Tumor Antigens ◽

Host Immune System ◽

Primary Tumors ◽

Novel Approach ◽

Tumor Environment ◽

Advanced Biomaterials

AbstractBreast cancer continues to be the most frequently diagnosed malignancy among women, putting their life in jeopardy. Cancer immunotherapy is a novel approach with the ability to boost the host immune system to recognize and eradicate cancer cells with high selectivity. As a promising treatment, immunotherapy can not only eliminate the primary tumors, but also be proven to be effective in impeding metastasis and recurrence. However, the clinical application of cancer immunotherapy has faced some limitations including generating weak immune responses due to inadequate delivery of immunostimulants to the immune cells as well as uncontrolled modulation of immune system, which can give rise to autoimmunity and nonspecific inflammation. Growing evidence has suggested that nanotechnology may meet the needs of current cancer immunotherapy. Advanced biomaterials such as nanoparticles afford a unique opportunity to maximize the efficiency of immunotherapy and significantly diminish their toxic side-effects. Here we discuss recent advancements that have been made in nanoparticle-involving breast cancer immunotherapy, varying from direct activation of immune systems through the delivery of tumor antigens and adjuvants to immune cells to altering immunosuppression of tumor environment and combination with other conventional therapies.

Download Full-text

ФАРМАКОЛОГІЧНА ДІЯ ПРЕПАРАТУ «ЕКОСОРБ 25» ТА ВПЛИВ НА РІВЕНЬ НАПРУЖЕНОСТІ ІМУНІТЕТУ СВИНЕЙ, ЩО ЗНАХОДЯТЬСЯ НА ВІДГОДІВЛІ

Scientific Messenger of LNU of Veterinary Medicine and Biotechnology ◽

10.15421/nvlvet7117 ◽

2016 ◽

Vol 18 (3(71)) ◽

pp. 75-78

Author(s):

Zh. Rybachuk

Keyword(s):

Immune System ◽

Immune Status ◽

Positive Influence ◽

Mean Value ◽

Control Group ◽

System Reduction ◽

Group Content ◽

Wide Range ◽

The Difference ◽

The Given

In the articles resulted the uses of preparation given inrelation to expediency are with adsorbent properties of «Еcosorb 25» for pigs that are on fattening. Undertakenstudies it is well–proven that introduction in the complementof ration of the indicated adsorbent from a calculation 5 kg/1the ton of forage is predetermined by an increase in the serum of blood of content of immunoproteins. Content ofimmunoproteins is in the serum of blood of pigs, that it isexposed to research to application of adsorbent was differentand was in a wide range, a mean value was 15.9 ± 3.2 gs/l immune status of investigational population is different Accordingly. Consider that such wide range of data testifiesto different activity of functioning of the immune system andconditioned by the different antigen loading each ofinvestigationalanimals. In a 21 twenty–four hours, after thebeginning of application of adsorbent of «Еcosorb 25» content of immunoproteins in the serum of blood of pigs of anexperience group is considerably less in comparing to theanimals that in composition a ration got «Ecosorb 25». Forthese pigs (control group) content of immunoproteins was at the level of a 16.6 ± 1.27g/l, but substantially differed for every animal, that testifiedtheir immune status to different. For the pigs of an experiencegroup a difference is between the least and maximal index ofcontent of immunoproteins presented 17.8% that specified onalmost identical reactivity of the immune system (reduction ofreceipt of antigens, maybe and mycotoxins from agastrointestinal tract). Got the given is conditioned by thedisplay of adsorbent action of preparation that is entered to the ration of pigs of an experience group. Positive influence of «Ecosorb 25» on functioning of the immune system atintroduction to the ration of pigs that are on fattening, theresults of research of serum of blood testify through 2 missesafter the beginning of application. Reduction to content of immunoproteins is registered in theserum of blood of pigs of control group on 15.7% comparing to the previous index (21twenty–four hours) and 19.5% animals of an experience group. For certain (Р ≥ 0,99) contentof immunoproteins increased in the serum of blood of pigs ofan experience group 17 ± 0.25 gs/of to 14.0 ± 0.76 g/l that maybe it contingently the receipt of substances with animmunodepressive action (including and micotoxins) in the organism of animals of control group. Id est, at feeding to the pigs of preparation of «Ecosorb 25» with adsorbent properties during 2th months, stipulated reduction of receiptof toxins in blood, and accordingly and reduction offunctional activity immune. It provides rapid reactivity of the immune system andsynthesis of sufficient amount of antibodies at the hit ofmicroorganisms to the organism of pigs, that in compositiona ration got an adsorbent. As for the animals of control group registered reduction to content of immunoproteins in theserum of blood, it testifies to weakening of functional activityof the immune system. The difference of content ofimmunoproteins in the serum of blood of pigs testifies to the increase of providing of better immunological defence in the organism of animals of anexperience group and reduction of him in a control group.

Download Full-text

The Effect of Hyperbaric Oxygen Therapy to the Amount of Lymphocytes in Oral Candidiasis Immunosuppressed Model

DENTA ◽

10.30649/denta.v12i2.164 ◽

2019 ◽

Vol 12 (2) ◽

pp. 36

Author(s):

Agni Febrina Pargaputri ◽

Dwi Andriani

Keyword(s):

Immune System ◽

Hyperbaric Oxygen ◽

Hyperbaric Oxygen Therapy ◽

Wistar Rats ◽

Oxygen Therapy ◽

Oral Candidiasis ◽

Control Group ◽

Control Group Design ◽

Significant Difference ◽

The Difference

Background: Oral candidiasis generally caused by Candida albicans with prevalence of 30-50%. C. Albicans proliferation in the oral cavity was canducted by decreasing immune system of the host. Lymphocytes activation in immune system happened when there is a contact between host cell with cell wall of C. albicans as a result of C. albicans antigen. One of therapy to suppress the Candida infection sistemically is by giving hyperbaric oxygen therapy. Purpose: To determine the effects of giving hyperbaric oxygen therapy to the amount of lymphocytes in oral candidiasis immunosuppressed models. Methods: This research was post test only control group design. We used 12 wistar rats which were divided into 3 groups(n=4/3): K-(normal/ healthy wistar rats), K+(oral candidiasis immunosuppressed wistar rats), P1(oral candidiasis immunosuppressed wistar rats which were given hyperbaric oxygen therapy 5 days). K+ and P1 groups were immunosuppressed by giving dexamethasone 0,5mg/day/rat orally for 14 days, added with tetrasiklin 1 mg/day/rat. On the 3rd day immunosuppression, the rats were inducted with C.albicans smeared in the dorsum linguae once every two days for 12 days. Results: The data were analyzed with one way Anova test and showed significant difference among groups (p<0,05). To show the difference between each groups we used LSD test and showed significant difference (p<0,05) between K+ compared with P1, and K+ compared with K-. Conclusion: Hyperbaric oxygen therapy gives effect to the amount of lymphocytes in oral candidiasis immunosuppressed models. Keywords: Oral candidiasis, immunosuppressed, hyperbaric oxygen therapy, lymphocytes Correspondence: Agni Febrina Pargaputri, Department of Oral Biology Faculty of Dentistry, Jl. Arif Rahman Hakim 150, Surabaya, Indonesia. Phone: 031-5945864, fax: 031-5912191, Email: agni.febrina@hangtuah.ac.id

Download Full-text

Simple and effective bacterial-based intratumoral cancer immunotherapy

Journal for ImmunoTherapy of Cancer ◽

10.1136/jitc-2021-002688 ◽

2021 ◽

Vol 9 (9) ◽

pp. e002688

Author(s):

Christina S E Carroll ◽

Erin R Andrew ◽

Laeeq Malik ◽

Kathryn F Elliott ◽

Moira Brennan ◽

...

Keyword(s):

Immune System ◽

Tumor Growth ◽

Cancer Immunotherapy ◽

Cancer Patients ◽

Immune Cell ◽

Human Cancer ◽

Intratumoral Injection ◽

Ct Scans ◽

Antitumor Effects ◽

Wide Range

BackgroundWe describe intratumoral injection of a slow-release emulsion of killed mycobacteria (complete Freund’s adjuvant (CFA)) in three preclinical species and in human cancer patients.MethodsEfficacy and safety were tested in mammary tumors in mice, in mastocytomas in mice and dogs, and in equine melanomas. In mice, survival, tumor growth, and tumor infiltration by six immune cell subsets (by flow cytometry) were investigated and analyzed using Cox proportional hazards, a random slopes model, and a full factorial model, respectively. Tumor growth and histology were investigated in dogs and horses, as well as survival and tumor immunohistochemistry in dogs. Tumor biopsies were taken from human cancer patients on day 5 (all patients) and day 28 (some patients) of treatment and analyzed by histology. CT scans are provided from one patient.ResultsSignificantly extended survival was observed in mouse P815 and 4T1 tumor models. Complete tumor regressions were observed in all three non-human species (6/186 (3%) of mouse mastocytomas; 3/14 (21%) of canine mastocytomas and 2/11 (18%) of equine melanomas). Evidence of systemic immune responses (regression of non-injected metastases) was also observed. Analysis of immune cells infiltrating mastocytoma tumors in mice showed that early neutrophil infiltration was predictive of treatment benefit. Analysis of the site of mastocytoma regression in dogs weeks or months after treatment demonstrated increased B and T cell infiltrates. Thus, activation of the innate immune system alone may be sufficient for regression of some injected tumors, followed by activation of the acquired immune system which can mediate regression of non-injected metastases. Finally, we report on the use of CFA in 12 human cancer patients. Treatment was well tolerated. CT scans showing tumor regression in a patient with late-stage renal cancer are provided.ConclusionOur data demonstrate that intratumoral injection of CFA has major antitumor effects in a proportion of treated animals and is safe for use in human cancer patients. Further trials in human cancer patients are therefore warranted. Our novel treatment provides a simple and inexpensive cancer immunotherapy, immediately applicable to a wide range of solid tumors, and is suitable to patients in developing countries and advanced care settings.

Download Full-text

The effect of different doses of bevacizumab and irinotecan on tumor growth of nude mice bearing human colon cancer DLD-1.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.3_suppl.518 ◽

2014 ◽

Vol 32 (3_suppl) ◽

pp. 518-518

Author(s):

Luo Cong

Keyword(s):

Colon Cancer ◽

Tumor Growth ◽

Nude Mice ◽

Tumor Angiogenesis ◽

Human Colon ◽

Control Group ◽

Human Colon Cancer ◽

Group A ◽

Group B ◽

Different Doses

518 Background: Anti-angiogenic therapy is an important therapeutic strategy in advanced colorectal cancer. However, the anti-angiogenic drug,such as bevacizumab(avastin) is expensive. So, clarifying whether different doses of avastin play the same effect in vivo is urgently needed. The aim of the study was to observe the different doses of avastin in combination with irinotecan in human colon tumor growth in nude mice and tumor angiogenesis. Methods: 21 nude mice inoculated with DLD-1 human colon cancer cells were randomly divided into four groups: sterile saline control (group A), 5mg/kg avastin plus irinotecan chemotherapy group (group B), 10mg/kg avastin plus irinotecan group (group C), and irinotecan chemotherapy group (group D). Drugs were administered in the first 1,5,9 days, mice were sacrificed in the 10th day after treatment, the tumor growth inhibitory rate was calculated and the tumor microvessel density (MVD) were detected by immunohistochemistry. Results: The tumor inhibition rate in groups B, C, and D were 62.85%, 47.91%, 39.59% respectively. A, B, C, and D groups’ MVD were 7.000 ± 0.71, 4.940 ± 0.58, 5.080 ± 1.25, 5.557 ± 2.04, The MVD in group B and C were significant different compared with group A by Dunnett's test, and the MVD expression difference between D, A groups and B, C groups did not reach statistical significance (P values were 0.086,0.083). Tissue necrosis was found in each group after HE staining of tumor tissue. Among them, the control group, mostly mild to moderate necrosis, and the necrosis area were increased after drug treatment. But there were no statistical differences of the necrotic area in drug treated groups graded by rank sum test (χ2 = 4.73, P = 0.193). And cell apoptosis was obviously seen in treated groups. Conclusions: Different doses of avastin with irinotecan inhibited the tumor growth on DLD-1 xenografted nude mice, Synergistic effects were observed in combination therapy, From cell morphology changes after staining with HE, we speculated that the mechanism may be related to the inhibition of tumor angiogenesis, and cell apoptosis increasing. The effect of 5mg/kg and 10mg/kg bevacizumab on tumor volume and MVD had no significant differences.

Download Full-text

Serum Vitamin Profile in Oral Lichen Planus Patients in Southwest of Iran

BioMed Research International ◽

10.1155/2021/8627435 ◽

2021 ◽

Vol 2021 ◽

pp. 1-7

Author(s):

Fahimeh Rezazadeh ◽

Sara Haghighat

Keyword(s):

Immune System ◽

Lichen Planus ◽

Oral Lichen Planus ◽

Serum Levels ◽

Control Group ◽

Related Disorder ◽

Significant Difference ◽

The Difference ◽

Southwest Of Iran ◽

Oral Lichen

Introduction. Oral lichen planus (OLP) is a chronic mucocutaneous disease. It is mainly an immune system-related disorder. Vitamins can modulate immune system functions, and thus, vitamin deficiency might have roles in exacerbating OLP. We aim to determine the serum levels of vitamins A, B12, C, D3, and E in OLP patients. Methods and Materials. 34 OLP patients referred to Shiraz Dental School entered the study. Blood samples were collected and levels of A, B12, C, D3, and E vitamins were measured in serum. 43 healthy people were also included as the control group. Serum levels of vitamins were measured by HPLC (A, B12, D3, and E) and Kiazist analyzing kit (vitamin C). Results. Most of the patients were female (62.3%), and the mean age of patients was 48.03 ± 11.57 . Serum levels of vitamins A, C, and E were lower in OLP patients in comparison with the healthy group; however, the difference was not significant. Vitamins B12 and D3 were higher in the OLP group but the difference was not significant. Conclusion. Serum levels of vitamins A, B12, C, D3, and E do not have a significant difference in OLP patients and healthy groups. These vitamins may not have a considerable role in OLP pathogenesis in the southwest of Iran.

Download Full-text

Role of the Immune System in the Growth of an Isotransplanted Urethan-Induced Lymphosarcoma

Tumori Journal ◽

10.1177/030089166905500402 ◽

1969 ◽

Vol 55 (4) ◽

pp. 189-195 ◽

Cited By ~ 2

Author(s):

Giorgio Parmiani ◽

Giusi Carbone

Keyword(s):

Immune System ◽

Tumor Growth ◽

Inhibitory Action ◽

Cell Suspensions ◽

Neoplastic Cells ◽

Thymic Lymphoma ◽

Hybrid Combination

Two groups of (SWR×C57BL)F1 mice were injected subcutaneously with two quantitatively different cell suspensions from a uretan-induced thymic lymphoma of the same hybrid combination. Each of these groups was divided before the neoplastic isograft into the following sub-groups: controls, cyclophosphamide injected, X-irradiated and BCG injected mice. Percentage of takes, tumor diameters and mortality provided the parameters for the evaluation of the tumor growth. With the higher inoculum of neoplastic cells (5×105) only cyclophosphamide was effective in enhancing the take percentage 10 days after the isograft. With the smaller inoculum (5 × 103) all treatments were effective on tumor growth although the inhibitory action of BCG was not as strong as the enhancing action of the immune depressive treatments. The results are interpreted as evidence of a specific antigenicity of urethan-induced lymphoma.

Download Full-text

Immune Therapy in GI Malignancies: A Review

Journal of Clinical Oncology ◽

10.1200/jco.2015.60.7879 ◽

2015 ◽

Vol 33 (16) ◽

pp. 1745-1753 ◽

Cited By ~ 23

Author(s):

Judy Wang ◽

Kim A. Reiss ◽

Rina Khatri ◽

Elizabeth Jaffee ◽

Dan Laheru

Keyword(s):

Immune System ◽

Immune Responses ◽

Immune Suppression ◽

Immune Therapy ◽

Immune Recognition ◽

Systemic Factors ◽

Tumor Environment ◽

The Difference ◽

Complex Relationships

The balance between tumor-promoting and tumor-suppressing immune responses and the difference between them ultimately determine whether a cancer escapes immune recognition mechanisms. Defining the complex relationships between the tumor itself, the tumor environment, and the immune system has been critical in facilitating the development of successful immunotherapies. This review explores the role of oncogenes in inducing cancer-associated inflammation, the local and systemic factors that lead to immune suppression, and immunotherapy approaches to overcome immune privilege.

Download Full-text

Weichang’an Formula Inhibits Tumor Growth in Combination with Bevacizumab in a Murine Model of Colon Cancer—Making up for the Deficiency of Bevacizumab by inhibiting VEGFR-1

Frontiers in Pharmacology ◽

10.3389/fphar.2020.512598 ◽

2020 ◽

Vol 11 ◽

Author(s):

Chuan-Fang Pan ◽

Xi Zhang ◽

Jing-Wen Wang ◽

Tao Yang ◽

Linda L. D. Zhong ◽

...

Keyword(s):

Colon Cancer ◽

Protein Expression ◽

Tumor Growth ◽

Mrna Expression ◽

Human Colon ◽

Control Group ◽

Human Colon Cancer ◽

Target Proteins ◽

Protein Levels ◽

Hct 116

Aim: Angiogenesis plays an important role in the initiation, development, and metastasis of malignant tumors. Antiangiogenic drugs combined with immune therapy are considered to have a synergistic effect on anti-tumor strategy. Weichang’an formula (WCAF) is a prescription of traditional Chinese medicine (TCM) based on pharmaceutical screening and clinical experience. The aim of this study is to examine the effect of WCAF and its combined action with Bevacizumab (BEV) in colorectal cancer, and to identify the possible mechanism of action.Methods: A human colon cancer cell (HCT 116) subcutaneous xenograft model was established in BALB/c-nu/nu mice. Tumor-bearing mice were randomized into each of four groups: control, WCAF treated, BEV treated, and WCAF plus BEV treated. Apoptosis was detected by TUNEL assay. Western blot was used to assess the protein levels of Leptin-R, STAT3, p-STAT3, BCL-2, and VEGFR-1. Immunohistochemistry was used to detect the micro-vessel density (MVD) and AKT1. Leptin and Vascular endothelial growth factor A (VEGF-A) mRNA expression were detected by Real-time PCR (RT-PCR). A network pharmacology study and validation assay were carried out to find the underlying molecular targets of WCAF related to immune regulation.Results: Compared with the control group, WCAF reduced tumor weight and volume, as well as promoted tumor cell apoptosis. WCAF treatment decreased the mRNA expression of Leptin and VEGF-A, while the protein levels of CD31, LEP-R, VEGFR-1, STAT3, and p-STAT3 were decreased in tumor tissues. In addition, VEGFR-1 protein expression was decreased in the WCAF group and the WCAF plus BEV group but not in the BEV group. The combination of WCAF and BEV demonstrated a partial additive anti-tumor effect in vivo. The pharmacological network also found there are 26 WCAF target proteins related to cancer immune and 12 cancer immune related pathways. The AKT1 protein expression in the WCAF and WCAF + BEV groups were significantly lower than the that in the control group (p < 0.01).Conclusion: WCAF can inhibit tumor growth and promote apoptosis and inhibit tumor angiogenesis in subcutaneous xenografts of human colon cancer HCT-116 in nude mice. WCAF also makes up for the deficiency of BEV by inhibiting VEGFR-1. The VEGFR-1 expression between the combination group and BEV alone achieved statistically significant difference (p < 0.01). Combined with BEV, WCAF showed a partial additive anti-tumor effect. The mechanism may be related to Leptin/STAT3 signal transduction, VEGF-A, VEGFR-1 and WCAF target proteins related to cancer immune such as leptin and AKT1.

Download Full-text